Clinical Efficacy Of Shenqi Pill Combined With Endocrine Therapy In The Treatment Of Hormone-sensitive Prostate Cance

Objective: To study the clinical efficacy and safety of traditional Chinese patent medicines and simple preparations Shenqi Pill combined with endocrine therapy for hormone sensitive prostate cancer.Methods: 39 patients diagnosed with HSPC and meeting the inclusion criteria at the First Affiliated Hospital of Hunan University of Traditional Chinese Medicine and Mayang County Hospital of Traditional Chinese Medicine from April 1,2021 to December 31,2022 were randomly divided into two groups.The control group was treated with ADT regimen(drug castration or surgical castration),and the treatment group was treated with Shenqi pill orally on the basis of the control group.Collect,sort out and analyze the baseline data of the two groups of patients,and conduct a period of clinical observation(3months)for the two groups of patients.Compare the differences between the two groups of patients in PSA level,quality of life,traditional Chinese medicine syndrome score,sleep quality and other aspects and the related adverse events after treatment with ANOVA and chi square test.Results: A total of 39 subjects were included in this study,including 19 patients in the treatment group and 20 patients in the control group.Patients in both groups regularly completed one cycle(3 months)of treatment.Before treatment,the baseline data(age,PSA level,TCM syndrome score,etc.)of the two groups had no statistical difference(P>0.05),which means that the baseline data of patients in different treatment schemes were basically balanced and comparable;During the3-month treatment,the comparison between groups found that:(1)the PSA level of patients in the two groups was not statistically significant,but the PSA level in the treatment group was significantly lower than that in the control group,and the PSA response rate of the two groups was subsequently compared,and the PSA 50 and PSA 90 in the treatment group were significantly better than that in the control group;(2)Compared with the control group,the quality of life score of the treatment group was P<0.05,and the score was significantly better than that of the control group.The quality of life scale was divided into five aspects,including physiological conditions.The treatment group had statistical differences compared with the control group in terms of social,family and other conditions,and was significantly better than the control group;(3)The syndrome of kidney yang deficiency and blood stasis in the treatment group was significantly better than that in the control group,and the comparison values were statistically different.(4)There was no significant difference in sleep between the two groups,and the score of the treatment group was slightly better than that of the control group.(5)After treatment,the related adverse reactions of the two groups of patients were mild,and there was no statistical difference.The top ranked patients were lower nutritional status,lower blood calcium,etc.Conclusion:The addition of Shenqi Pill on the basis of endocrine therapy can effectively control the PSA level of hormone sensitive prostate cancer patients,improve the PSA response rate,improve the quality of life of patients,alleviate kidney yang deficiency and blood stasis syndrome,and has high safety without obvious side effects.